Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05577819
Other study ID # 2020P002061
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2020
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Massachusetts General Hospital
Contact Abbie Macher, BS
Phone 617-643-6328
Email ajmacher@mgh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.


Description:

Patients 65-years and older with HFpEF will be enrolled to participate in this single center, event driven (positive nuclear amyloid scan also known as 99mTc-pyrophosphate SPECT scan) study. During the single study visit the following will be obtained: - 99mTc-pyrophosphate SPECT scan - Blood and DNA (optional) sample collection - Questionnaires in regards to neuropathy, carpal tunnel, frailty, and Heart failure symptoms and how they may affect ones quality of life - 6-Minute Walk Test - ECG (electrocardiogram) - Echocardiogram Electronic health records will be reviewed for up to 5 years in order to determine hospitalization and survival of the study participants. Clinical outcomes of interest include a combined endpoint of days alive outside of the hospital from heart failure hospitalizations at one and five years, presence of autonomic neuropathy, presence of carpal tunnel syndrome, presence of polyneuropathy. Additionally, Individual clinical endpoints are also endpoints of interest. The results from this study will be used to determine how frequently heart failure patients have transthyretin amyloidosis in their heart and better understand their symptoms. We hope that better understanding transthyretin amyloidosis in heart failure patients will help us identify affected patients so that they can receive treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 515
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Patients with a confirmed diagnosis of HFpEF. - Age =65 years old Exclusion Criteria: - End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR <15mL/min) - no history of HFrEF (LVEF<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc - Negative 99mTc-pyrophosphate scan within a year - Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan - Known diagnosis of amyloidosis - Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)

Study Design


Intervention

Diagnostic Test:
99mTc-pyrophosphate Scintigraphy
Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (5)

Lead Sponsor Collaborator
Massachusetts General Hospital Akcea Therapeutics, Alnylam Pharmaceuticals, Eidos Therapeutics, a BridgeBio company, Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Presence of autonomic neuropathy Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events Time from study Visit until the date of documented event up to 5 years after the study closure
Other Presence of carpal tunnel syndrome Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events Time from study Visit until the date of documented event up to 5 years after the study closure
Other Presence of polyneuropathy Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events Time from study Visit until the date of documented event up to 5 years after the study closure
Other Combined endpoint of days alive outside of hospital from HF hospitalizations at one and five years Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events Time from study Visit until the date of documented event up to 5 years after the study closure
Other Individual endpoints of all-cause mortality, cardiovascular mortality, all-cause hospitalizations, cardiovascular hospitalizations and HF hospitalizations. Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events Time from study Visit until the date of documented event up to 5 years after the study closure
Primary Diagnosis of 99mTc-pyrophosphate scan positive ATTR A cardiac disease in which misfolded proteins aggregate into amyloid fibril and deposit interstitially, leading to diastolic dysfunction and heart failure Day 1 (day of study visit)
Secondary New York Heart Association function classification Classifies the severity of a patients Heart Failure in terms of their limitations during physical activity Day 1 (day of study visit)
Secondary Impact of HF as assessed by Kansas City Cardiomyopathy Questionnaire Kansas City Cardiomyopathy Questionnaire is a questionnaire that determines in the impact of Heart Failure on their health status, such as quality of life, symptoms, function, etc.) Day 1 (day of study visit)
Secondary Exercise capacity as determined by a 6-minute walk test The 6 minute walk test is used to determine an objective measurement of a patients aerobic capacity and endurance Day 1 (day of study visit)
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy